538
Participants
Start Date
February 29, 2012
Primary Completion Date
January 31, 2014
Study Completion Date
January 31, 2014
GLIMEPIRIDE
"Pharmaceutical form: oral~Route of administration: oral"
METFORMIN
"Pharmaceutical form: oral~Route of administration: oral"
Investigational Site Number 170001, Manizales
Investigational Site Number 78803, La Marsa
Investigational Site Number 78804, La Marsa
Investigational Site Number 710-002, Durban
Investigational Site Number 710-001, Durban
Investigational Site Number 01205, Sétif
Investigational Site Number 01203, Oran
Investigational Site Number 792-001, Istanbul
Investigational Site Number 792-006, Istanbul
Investigational Site Number 484002, Guadalajara
Investigational Site Number 484003, Guadalajara
Investigational Site Number 784-004, Sharjah city
Investigational Site Number 792-005, Sivas
Investigational Site Number 643003, Moscow
Investigational Site Number 356009, Lucknow
Investigational Site Number 643002, Saratov
Investigational Site Number 356008, Pune
Investigational Site Number 356007, Nashik
Investigational Site Number 356003, Indore
Investigational Site Number 356001, Bangalore
Investigational Site Number 356002, Bangalore
Investigational Site Number 364001, Tehran
Investigational Site Number 364002, Tehran
Investigational Site Number 01206, Algeries
Investigational Site Number 17003, El Espinal
Investigational Site Number 81801, Cairo
Investigational Site Number 81802, Cairo
Investigational Site Number 81803, Cairo
Investigational Site Number 32001, Guatemala City
Investigational Site Number 32002, Guatemala City
Investigational Site Number 32003, Guatemala City
Investigational Site Number 32004, Guatemala City
Investigational Site Number 356006, Ernākulam
Investigational Site Number 356010, Mumbai
Investigational Site Number 356005, Varanasi
Investigational Site Number 36403, Tehran
Investigational Site Number 42201, Beirut
Investigational Site Number 42202, Beirut
Investigational Site Number 42203, Chouf
Investigational Site Number 422004, Hazmiyeh
Investigational Site Number 643001, Saint Petersburg
Investigational Site Number 78805, Sfax
Investigational Site Number 78801, Tunis
Investigational Site Number 78802, Tunis
Investigational Site Number 78806, Tunis
Investigational Site Number 78807, Tunis
Investigational Site Number 792-004, Adana
Investigational Site Number 792-002, Kütahya
Investigational Site Number 804003, Zaporizhzhya
Investigational Site Number 784-001, Dubai
Investigational Site Number 784-002, Dubai
Investigational Site Number 784-003, Dubai
Investigational Site Number 792-003, Antalya
Investigational Site Number 804001, Kyiv
Investigational Site Number 804002, Kyiv
Lead Sponsor
Sanofi
INDUSTRY